Search

everythinglearnresearchcommunity

for

Search:↓

Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.

VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.

A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

Topical GT20029 effectively promotes hair regrowth and is well-tolerated for treating androgenetic alopecia.

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.

Further testing of paclitaxel poliglumex for this cancer treatment is not justified.

Tofacitinib effectively treated severe alopecia areata in a 14-year-old girl.

Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.

5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.

Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.

New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.

Tofacitinib helped regrow hair in a lupus patient with alopecia.

Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.

The new gel combining minoxidil and tofacitinib effectively treats alopecia areata by promoting hair growth and reducing inflammation.

Baricitinib works better than methotrexate for severe alopecia areata.

Inhibitors of 11β-HSD1 show potential for treating type 2 diabetes but require more testing for safety and effectiveness.

The method effectively measures drug impact on DHT levels in prostate treatments.

Dutasteride reduces DHT more effectively than finasteride.

Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.

Baricitinib helps regrow hair in teens with severe alopecia areata.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.

Dutasteride effectively treats hair loss and prostate issues.

Afatinib often causes skin problems that need proactive management.

Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.

A man's bald spot grew hair after starting cancer treatment with gefitinib.

Non-daily Dutasteride is more cost-effective and has lower cancer incidence than daily treatment.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.